A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Grants and Contracts Details

StatusFinished
Effective start/end date11/12/07 → 3/31/10

Funding

  • AMGen: $38,069.00